Canton Strategic Holdings, Inc. (CNTN)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Canton Strategic: Highly Intriguing Blockchain Treasury With Tangible Risks
Canton Strategic Holdings, Inc. has pivoted from biotech to a pure-play blockchain treasury, focusing on Canton Coin and Super Validator operations. CNTN's business model centers on acquiring and operating digital assets, with a unique network structure targeting institutional adoption and privacy-driven blockchain solutions. Despite significant operational progress and notable institutional backing, CNTN remains pre-revenue, loss-making, and exposed to regulatory, custodial, and adoption risks.
Canton Strategic Holdings, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 3 | $8.46 | $5.7 | -$2.76 | -32.62% |
| BG Bart Gancher Intech Investment Management LLC | 10,906 | $30,754.92 | $20,394.22 | -$10,360.7 | -33.69% |
 Joseph Castro Nuveen LLC | 59,500 | $167,790 | $111,265 | -$56,525 | -33.69% |
 Robert Tutela Essex LLC | 22,902 | $68,440.59 | $44,200.86 | -$24,239.73 | -35.42% |
 Hui Fai Tam Caitong International Asset Management Co. Ltd. | 55 | $156.91 | $106.15 | -$50.76 | -32.35% |
Canton Strategic Holdings, Inc. (CNTN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Canton Strategic Holdings, Inc. ever had a stock split?
Canton Strategic Holdings, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mark Wendland CEO | NASDAQ (NMS) Exchange | 432705309 CUSIP |
| US Country | 12 Employees | - Last Dividend | 28 May 2024 Last Split | - IPO Date |
Overview
Canton Strategic Holdings, Inc. is a forward-thinking company dedicated to integrating blockchain technology within institutional finance through the use of Canton Coin and the development of the Canton network. The company's goal is to spearhead the adoption of blockchain solutions, fostering the digitization of financial markets. In addition to blockchain initiatives, Canton Strategic Holdings is engaged in the research and development of innovative medical technologies. Noteworthy projects include GV104 and GV023, which focus on addressing critical healthcare challenges, particularly in military and emergency response contexts. Originally founded as Tharimmune, Inc. in 2017, the company rebranded to Canton Strategic Holdings, Inc. in February 2026, with its headquarters located in Red Bank, New Jersey.
Products and Services
- Canton Coin: A digital currency designed to facilitate transactions within the Canton network, aimed at promoting the broader adoption of blockchain within institutional finance.
- Canton Network: A framework supporting the utilization of blockchain technology to enhance the efficiency and transparency of financial markets.
- GV104: A buccal film technology developed to address respiratory and/or nervous system depression, specifically for use in military personnel and chemical incident responders. This product has successfully completed Phase 1 trials.
- GV023: An oral formulation of infliximab, designed to overcome limitations of traditional IV treatments by eliminating the need for repeated intravenous infusions, thus alleviating the treatment burden for patients.
